Serum lysozyme activity in some myeloproliferative diseases

Area of Science:

• Hematology
• Biochemistry
• Oncology

Background:

• Myeloproliferative diseases are a group of conditions affecting the bone marrow.
• Lysozyme, an enzyme, plays a role in immune function and is found in serum.
• Altered serum lysozyme activity can be indicative of various hematological disorders.

Purpose of the Study:

• To investigate serum lysozyme activity in patients with myeloproliferative diseases.
• To differentiate lysozyme activity patterns between different types of leukaemia and pancytopenia.
• To explore the effect of serum dilution on lysozyme activity measurements.

Main Methods:

• Serum samples were collected from patients diagnosed with myeloproliferative diseases, including chronic myelogenous leukaemia (CML), acute myelogenous leukaemia (AML), chronic lymphatic leukaemia (CLL), and pancytopenia (P).
• Lysozyme activity was measured in both undiluted and tenfold diluted serum samples.
• Statistical analysis was performed to compare lysozyme activity levels across different patient groups and with control values (implied).

Main Results:

• Significantly increased serum lysozyme activity was observed in patients with CML and CLL.
• Serum lysozyme activity remained unchanged in patients with AML and pancytopenia.
• Lysozyme activity measurements showed enhancement upon tenfold dilution of the serum samples.

Conclusions:

• Elevated serum lysozyme activity is a potential biomarker for CML and CLL.
• The observed enhancement of lysozyme activity upon dilution suggests the presence of inhibitory factors in the sera of patients.
• These findings may have diagnostic implications for differentiating myeloproliferative neoplasms.